P Tappenden

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis
    Jim Chilcott
    School of Health and Related Research Rapid Reviews Group, School of Health and Related Research, University of Sheffield
    BMJ 326:522; discussion 522. 2003
  2. ncbi Methodological issues in the economic analysis of cancer treatments
    Paul Tappenden
    School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Eur J Cancer 42:2867-75. 2006
  3. ncbi Option appraisal of population-based colorectal cancer screening programmes in England
    Paul Tappenden
    School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Gut 56:677-84. 2007
  4. ncbi A stated preference binary choice experiment to explore NICE decision making
    Paul Tappenden
    School of Health and Related Research, The University of Sheffield, Sheffield, England
    Pharmacoeconomics 25:685-93. 2007
  5. ncbi Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case study
    Paul H Garthwaite
    Department of Mathematics and Statistics, The Open University, Milton Keynes, UK
    Int J Technol Assess Health Care 24:350-7. 2008
  6. ncbi Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework
    Paul Tappenden
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    Value Health 15:1127-36. 2012
  7. ncbi The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future
    Mark Pickin
    Medical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    BMC Neurol 9:1. 2009
  8. ncbi Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis
    P Tappenden
    Health Economics and Decision Science HEDS, School of Health and Related Research ScHARR, University of Sheffield, Sheffield, UK
    Bone Marrow Transplant 45:1014-21. 2010
  9. ncbi Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom
    Paul Tappenden
    University of Sheffield, Sheffield, UK
    Int J Technol Assess Health Care 25:470-8. 2009
  10. ncbi Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population
    Paul Tappenden
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Value Health 12:657-65. 2009

Detail Information

Publications34

  1. ncbi Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis
    Jim Chilcott
    School of Health and Related Research Rapid Reviews Group, School of Health and Related Research, University of Sheffield
    BMJ 326:522; discussion 522. 2003
    ..Price was the key modifiable determinant of the cost effectiveness of these treatments...
  2. ncbi Methodological issues in the economic analysis of cancer treatments
    Paul Tappenden
    School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Eur J Cancer 42:2867-75. 2006
    ....
  3. ncbi Option appraisal of population-based colorectal cancer screening programmes in England
    Paul Tappenden
    School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Gut 56:677-84. 2007
    ....
  4. ncbi A stated preference binary choice experiment to explore NICE decision making
    Paul Tappenden
    School of Health and Related Research, The University of Sheffield, Sheffield, England
    Pharmacoeconomics 25:685-93. 2007
    ..To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services...
  5. ncbi Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case study
    Paul H Garthwaite
    Department of Mathematics and Statistics, The Open University, Milton Keynes, UK
    Int J Technol Assess Health Care 24:350-7. 2008
    ..The purpose of this study is to describe the procedures used to quantify expert opinion and note examples of good practice contained in the case study...
  6. ncbi Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework
    Paul Tappenden
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    Value Health 15:1127-36. 2012
    ..This system-level approach can provide a consistent mathematical infrastructure for the economic evaluation of virtually any intervention across a disease pathway...
  7. ncbi The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future
    Mark Pickin
    Medical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    BMC Neurol 9:1. 2009
    ..This study aimed to assess the feasibility of risk sharing schemes, looking at long term clinical outcomes, to determine the price at which high cost treatments would be acceptable to the NHS...
  8. ncbi Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis
    P Tappenden
    Health Economics and Decision Science HEDS, School of Health and Related Research ScHARR, University of Sheffield, Sheffield, UK
    Bone Marrow Transplant 45:1014-21. 2010
    ..We conclude that HSCT could potentially achieve an acceptable level of cost-effectiveness. However, caution should be exercised as large, high-quality RCTs comparing HSCT versus mitoxantrone are necessary to validate these findings...
  9. ncbi Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom
    Paul Tappenden
    University of Sheffield, Sheffield, UK
    Int J Technol Assess Health Care 25:470-8. 2009
    ..The aim of this study was to examine the availability and consistency of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer...
  10. ncbi Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population
    Paul Tappenden
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Value Health 12:657-65. 2009
    ..To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) for the management of multiple sclerosis (MS) compared to best supportive care in the United States...
  11. ncbi The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    P Tappenden
    School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Eur J Cancer 43:2487-94. 2007
    ..The aim of this study is to estimate the cost-effectiveness of adding bevacizumab to chemotherapy for patients with untreated metastatic colorectal cancer...
  12. ncbi The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation
    A Pandor
    School of Health and Related Research (ScHARR, University of Sheffield, UK
    Health Technol Assess 10:iii-iv, xi-xiv, 1-185. 2006
    ....
  13. ncbi Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis
    D Papaioannou
    Health Economics and Decision Science HEDS, School of Health and Related Research ScHARR, University of Sheffield, Sheffield, UK
    Colorectal Dis 13:1085-99. 2011
    ..This review aimed to assess the present evidence on the effect of antioxidants on the incidence of colorectal neoplasms in the general population...
  14. ncbi The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation
    D Hind
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 12:iii-ix, xi-162. 2008
    ..To examine the role of irinotecan and oxaliplatin in reducing the extent of incurable disease before curative surgery (downstaging)...
  15. ncbi Chemoprevention of colorectal cancer: systematic review and economic evaluation
    K Cooper
    University of Sheffield, UK
    Health Technol Assess 14:1-206. 2010
    ..Individuals with these polyps undergo polypectomy and are invited for endoscopic surveillance. Screening via faecal occult blood testing has been rolled out across the UK...
  16. ncbi Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
    P Tappenden
    School of Health and Related Research ScHARR, University of Sheffield, UK
    Health Technol Assess 11:1-128, iii-iv. 2007
    ..To assess the clinical effectiveness and cost-effectiveness of bevacizumab and cetuximab in the treatment of individuals with metastatic colorectal cancer (CRC)...
  17. ncbi Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    S Eggington
    School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    Br J Cancer 95:1195-201. 2006
    ..Future research should attempt to elucidate uncertainties concerning the optimal roles of capecitabine and/or oxaliplatin in the adjuvant setting in order to achieve the maximum level of clinical benefit...
  18. ncbi A review and critique of modelling in prioritising and designing screening programmes
    J Karnon
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 11:iii-iv, ix-xi, 1-145. 2007
    ..Also to develop guidelines and an assessment checklist of good practice in the development of screening models...
  19. ncbi Meta-analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer
    C Carroll
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    Aliment Pharmacol Ther 31:708-18. 2010
    ..Folic acid has been identified as a possible agent for the chemoprevention of colorectal cancer...
  20. ncbi Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis
    P Tappenden
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 8:iii, 1-78. 2004
    ....
  21. ncbi Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review
    J Chilcott
    School of Health and Related Research ScHARR, Regent Court, Sheffield, UK
    Health Technol Assess 14:iii-iv, ix-xii, 1-107. 2010
    ..Numerous error avoidance/identification strategies could be adopted but it is difficult to evaluate the merits of strategies for improving the credibility of models without first developing an understanding of error types and causes...
  22. ncbi A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models
    R G Richards
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 6:1-73. 2002
  23. ncbi Simulation sample sizes for Monte Carlo partial EVPI calculations
    Jeremy E Oakley
    Department of Probability and Statistics, University of Sheffield, The Hicks Building, Hounsfield Road, Sheffield, S3 7RH, UK
    J Health Econ 29:468-77. 2010
    ..We test our algorithm using three case studies...
  24. ncbi Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer
    Eva Kaltenthaler
    School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Health Policy 87:389-400. 2008
    ....
  25. ncbi Modelling the expected net benefits of interventions to reduce the burden of medication errors
    Jonathan Karnon
    Department of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, UK
    J Health Serv Res Policy 13:85-91. 2008
    ....
  26. ncbi Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review
    Rachel J Jackson
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
    J Infect 62:14-25. 2011
    ..To systematically review evidence relating to the clinical efficacy of oseltamivir, zanamivir and amantadine in the prevention of influenza...
  27. ncbi Varenicline in the management of smoking cessation: a single technology appraisal
    D Hind
    ScHARR Technology Assessment Group, University of Sheffield, UK
    Health Technol Assess 13:9-13. 2009
    ....
  28. ncbi The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review
    P Tappenden
    School of Health and Related Research ScHARR, University of Sheffield, Sheffield, UK
    Health Technol Assess 16:1-72. 2012
    ..g. occupational therapists and physiotherapists), aim to positively affect health and functional status, and may promote independent functioning of older people...
  29. ncbi Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation
    P Tappenden
    University of Sheffield, School of Health and Related Research, UK
    Health Technol Assess 13:iii, ix-xii, 1-246. 2009
    ..To evaluate the clinical effectiveness and incremental cost-effectiveness of amantadine, oseltamivir and zanamivir for seasonal and post-exposure prophylaxis of influenza...
  30. ncbi A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative
    J Chilcott
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 7:iii-62. 2003
  31. ncbi Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal
    E L Simpson
    ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    Pharmacoeconomics 31:269-75. 2013
    ..33 days) for the initial hospitalization (ICER = £415). The Appraisal Committee (AC) gave a positive recommendation for bivalirudin for the treatment of adults with STEMI undergoing PPCI...
  32. ncbi A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus
    J Chilcott
    School of Health and Related Research, University of Sheffield, South Yorkshire, England
    Clin Ther 23:1792-823; discussion 1791. 2001
    ..There is a need for large-scale, long-term studies comparing the effectiveness of combination therapy that includes pioglitazone with that of other combinations of antidiabetic drugs...
  33. ncbi Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis
    Christopher Carroll
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom
    Clin Ther 32:789-803. 2010
    ..The aim of the review was to assess the evidence for the effectiveness of calcium in reducing the recurrence of adenomas and the occurrence of colorectal cancer among populations at high, intermediate, and low risk of the disease...
  34. ncbi The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative
    Jim Chilcott
    School of Health and Related Research (ScHARR, University of Sheffield, UK
    BJOG 111:903-7. 2004
    ..CONCLUSION: Routine antenatal anti-D prophylaxis provides a cost effective intervention for preventing haemolytic disease of the newborn in the pregnancies of women who are RhD-negative...